NextCell collaborates with T.A.D.1 and T1D app
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. Together, we want to spread hope for type 1 diabetes and make NextCell's clinical trials visible.
Every year, more than 900 children are diagnosed with type 1 diabetes and at least as many are diagnosed in adulthood. The disease has a huge impact on life and something that needs to be dealt with daily, for the rest of your life. In 2016, Elin Cederbrant founded "Together Against Diabetes 1" who has lived type 1 diabetes since 2010.
Through her lectures, the backpack project and through the T1D app, Elin has built a unique network and is recognized with high credibility in healthcare. Elin has been and is involved in several different development projects in regions and clinics with a great opportunity to influence. She has become an ambassador for type 1 diabetes in Sweden and through her social channels, T.A.D.1's project and her visibility in the media reaches out to a large part of those living with and around T1D in Sweden.
"Your whole life is turned upside down when you get your diagnosis and it is important for me to be able to help, both during the onset and every day of life with T1D. Nextcell Pharma's work and efforts give us with type 1 diabetes hope and I want to be part of spreading that," says Elin Cederbrant, founder of Together Against Diabetes 1.
Type 1 diabetes is an autoimmune disease in which its own immune system, for some reason, perceives the insulin-producing cells as dangerous and attacks them. NextCell's drug candidate (ProTrans) has been developed to reverse autoimmunity and thus stop the attac on insulin-producing cells. Treatment has been shown to be effective in clinical trials. Adult patients who have recently been diangostized with type 1 diabetes have received a single injection of ProTrans and then their change in body insulin production has been compared to patients receiving placebo. The patients treated with ProTrans have preserved a greater proportion of insulin compared to those receiving placebo. Some patients have even received increased insulin production as a result of treatment.
NextCell will conduct more studies to prove the efficacy in more patients and the goal is for ProTrans to be approved and become the standard treatment for type 1 diabetes. The treatment is given to protect residual insulin production and it is then important to start treatment as early as possible.
"NextCell wants to help raise awareness of diabetes and show that medical research is ongoing with positive results. We are extremely proud to partner with T.A.D.1 and the T1D app, which reaches virtually 100% of newly diagnosed in type 1 diabetes in Sweden. The backpack project is a unique platform to come in contact with people living with and close to type 1 diabetes," says Mathias Svahn, CEO NextCell.
For further information, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Home pages:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
About NextCell Pharma AB
NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 10% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.